Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

6.8K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.8K
Radiological Investigation III: Pulmonary Angiogram and PET Scan01:13

Radiological Investigation III: Pulmonary Angiogram and PET Scan

337
Radiological investigations are paramount in the diagnosis and management of various pulmonary diseases. Two essential investigations are the Pulmonary Angiogram and the Positron Emission Tomography (PET) Scan.
Pulmonary Angiogram
A Pulmonary Angiogram is an invasive procedure involving injecting a contrast medium through a catheter threaded into the pulmonary artery or the right side of the heart to visualize the pulmonary vasculature. Computed Tomography (CT) scans have mainly replaced this...
337
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

413
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
413
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

3.7K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
3.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeted Radionuclide Therapy: Current Landscape and Combination Approaches to Improve Oncology Outcomes.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Radiobiological comparison of holmium-166 and yttrium-90 for hepatocellular carcinoma treatment in vitro.

Nuclear medicine communications·2026
Same author

A Multicenter Phase II Randomized Controlled Trial Comparing 177Lu-Dotatate/Capecitabine Combination Treatment with 177Lu-Dotatate Monotherapy in Patients with Neuroendocrine Tumors.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

3SD: Rotational symmetry single-shot denoising in fluorescence microscopy.

Journal of microscopy·2026
Same author

Radiosensitization of NET cells by HSP90 inhibitor ganetespib is mediated through pleiotropic stress responses.

EJNMMI research·2025
Same author

Emerging Radiopharmaceuticals Beyond FDG for Ovarian Cancer: A Review of Advances in Nuclear Medicine.

Cancer medicine·2025

Related Experiment Video

Updated: Dec 27, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.4K

Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward.

Danny Feijtel1, Marion de Jong1, Julie Nonnekens1

  • 1Radiology & Nuclear Medicine, Erasmus Medical Center, Rotterdam, Netherlands.

Current Topics in Medicinal Chemistry
|February 27, 2020
PubMed
Summary

Peptide receptor radionuclide therapy (PRRT) effectively treats advanced neuroendocrine tumors (NETs). Further research into radiobiology and dosimetry is crucial for enhancing PRRT efficacy and patient outcomes.

Keywords:
Combination therapyNeuroendocrine tumors (NET)Peptide receptor radionuclide therapy (PRRT)RadiobiologyRadiopharmaceuticalsTherapeutic effects

More Related Videos

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.3K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.8K

Related Experiment Videos

Last Updated: Dec 27, 2025

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
09:49

A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods

Published on: April 24, 2020

10.4K
Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis
07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate RGD-peptide for Angiogenesis

Published on: January 7, 2019

7.3K
Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
09:06

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published on: February 3, 2023

1.8K

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiochemistry

Background:

  • Peptide receptor radionuclide therapy (PRRT) is a key treatment for metastatic neuroendocrine tumors (NETs).
  • Despite its effectiveness, PRRT does not cure all patients, necessitating research into improved therapeutic strategies.
  • Understanding the radiobiological response of cancer cells to PRRT is essential for optimizing treatment outcomes.

Purpose of the Study:

  • To review the development and clinical applications of PRRT for neuroendocrine tumors.
  • To explore strategies for enhancing PRRT efficacy, including novel radionuclides and peptide conjugates.
  • To highlight the importance of interdisciplinary collaboration in advancing PRRT.

Main Methods:

  • Review of existing literature on PRRT development, clinical outcomes, and emerging research.
  • Analysis of different radionuclides and peptide-conjugates used in PRRT.
  • Discussion of combinatorial treatment approaches and the role of dosimetry and radiobiology.

Main Results:

  • PRRT is a valuable treatment for metastatic NETs, but complete cure rates remain limited.
  • Various radionuclides and peptide-conjugates offer different therapeutic profiles and challenges.
  • Combinatorial treatments and improved understanding of radiobiology show promise for enhancing PRRT efficacy.

Conclusions:

  • PRRT has significantly advanced NET treatment, but further optimization is needed.
  • Future improvements in PRRT will likely involve tailored radionuclide selection, novel peptide targeting, and combination therapies.
  • Integrating dosimetry and radiobiology insights is critical for maximizing PRRT benefits in neuroendocrine tumor management.